The Curative Effect Of Zoledronic Acid In Treating Postmenopausal Osteoporosis

ObjectiveTo explore and analyze the curative effect of zoledronic acid in treating postmenopausal osteoporosis and the improvement of the lumbar vertebrae BMD and the right hip joint BMD.MethodsSelecting totally 60 cases of postmenopausal osteoporosis from 2012 to 2016 in our hospital who received treatment of zoledronic acid two times at least.The age range of patients:51 to 93 years,average (67.42±9.26) years.Every patients used calcitriol 0.5 μg per day and Calcium Carbonate D3 one tablet a day as the based treatment,and everyone used zoledronic acid 5mg once per year.Measured BMD and secrum calcium、 secrum phosphorus、ALP before treatment、one year after treatment and two years after treatment. Contrasted and analyzed the differences of these data in the three periods of treatment,and also can contrast the lumbar vertebrae BMD of pretherapy and post-treatment in each age groups(51-60years、61-70years、>70years).ResultsThe total lumbar vertebrae BMD. the BMD of each lumbar vertebrae(L1-L4), the right hip joint BMD after a year of treatment have significant differences with those before treatment(P<0.05).The total lumbar vertebrae BMD after two years of treatment has significant differences with those after a year of treatment(P<0.05).The right hip joint BMD after two years of treatment have no significant differences with those after a year of treatment(P>0.05).The lumbar vertebrae BMD in each age groups(51-60years、 61-70years、>70years) all have significant differences between pretherapy and post-treatment(P<0.05).Secrum calcium and secrum phosphorus has no significant differences between pretherapy and post-treatment(P>0.05).ALP of pretherapy are significant lower than that of the post-treatment (P<0.05).ConclusionUsing the zoledronic acid can increase the BMD of patients with postmenopausal osteoporosis, and the effect exist in each age groups.